with evidence that MDM2 destabilization of p53 is reand factors that induce cell cycle arrest and cell death.
duced in the presence of proteasome inhibitors (Haupt We can thus define events as being upstream or downet al., 1997; Kubbutat et al., 1997) . Grossman et al. (1998) stream of p53. The endpoint of the upstream compohave provided evidence that MDM2 needs to bind to nent of this pathway is that levels of the p53 protein the p300 transcriptional coactivator/histone acetylase are dramatically increased through posttranscriptional in order to mediate degradation of p53. Adding further mechanisms, often by one or two orders of magnitude.
complexity to this issue, Roth et al. (1998) have shown There is also evidence that in addition to elevating p53 that MDM2 shuttles p53 from the nucleus to the cytolevels, such signals convert the protein from an inert plasm where it is then degraded. We can undoubtedly form to one that is activated for sequence-specific tranexpect further clarification of the mechanism of MDM2-scriptional activation (reviewed in Ko and Prives, 1996) . mediated degradation of p53 in the near future. Stress signals are not the only means by which p53
Given the above information, it has become clear that becomes stabilized. The DNA viruses SV40 and adenovione way to stabilize and activate p53 in cells is by inrus encode gene products, T antigen and E1a, respecterfering either with the interaction between MDM2 and tively, that lead to increased quantities of p53 protein p53 or with the ability of MDM2 to target bound p53 for in cells. Moreover, under some conditions expression degradation. How might the p53-MDM2 interaction be of cellular factors such as Myc or Ras can also result regulated? At least two mechanisms can be envisaged, in p53 induction. Although this might seem at odds with one through changes in p53 due to covalent modificathe outcome of transformation caused by viral or cellular tion, and the other through noncovalent regulators of oncogenes, viruses and cells have evolved several ways the p53-MDM2 association. It is now apparent that both to counteract the growth suppression functions of inmechanisms can be identified under experimental conduced p53. The downstream component of the p53 ditions: DNA damage-induced phosphorylation of p53 pathway has been relatively well explored, and many can attenuate the p53-MDM2 interaction, and the prodtranscriptional targets of p53 have been identified and uct of the alternate reading frame (ARF) located within characterized, including the gene encoding the CDK the p16 INK4A locus (murine p19 ARF , human p14 ARF ) can bind inhibitor, p21. By contrast, the upstream component to MDM2 and prevent its destruction of p53. Interesthad been quite elusive until recently, and a number of ingly, these two mechanisms appear to be entirely sepasignificant breakthroughs have now provided insight rate and independent from each other, and regulated into this aspect of p53. While there are likely to be multithrough distinct signaling pathways. ple modes of induction of p53, current knowledge sugSignaling through Covalent Modification of p53 gests that diverse upstream signals funnel into a single
The phosphorylation status of a protein can have procritical interaction, namely that between p53 and its found consequences upon its function in cells. Given negative regulator, MDM2. that p53 is known to be responsive to a variety of stress p53 and MDM2 signals, considerable attention has focused on the deThe ability of p53 to either restrain or kill a cell must be termination of phosphorylation sites within the N-termireigned in under normal conditions. MDM2 accomnal activation region and the C-terminal regulatory doplishes this in two ways: as a result of its physical intermain ( Figure 1) . A number of human p53 sites have been action with p53, MDM2 both represses p53 transcripidentified that are known to be phosphorylated in vivo, tional activity and mediates the degradation of p53. The and several kinases have been identified that can phoslatter function of MDM2 was revealed when it was disphorylate these same sites in vitro. However, evidence covered that overexpression of MDM2 results in reis only indirect at present for utilization of some of the duced quantities of coexpressed p53, and that disrup-N-terminal sites. tion of the p53-MDM2 interaction by mutation results
One key technical breakthrough in determining stressin both activation and accumulation of p53 (Haupt et induced changes in phosphorylation has been the use of al., 1997; Kubbutat et al., 1997) . The region on p53 with phosphorylation site-specific antibodies. Such reagents which MDM2 interacts (residues 17-27) is interesting for have enabled the detection of specific constitutive or several reasons: First, it is one of the segments of p53 dynamic phosphorylation events with a sensitivity and that is highly conserved not only among different sperapidity that was previously impossible. Using such an cies, but even among some p53-related family memantibody, Ser15 was the first human p53 site shown to bers, such as p73. Second, this portion of p53 is located be inducibly phosphorylated after DNA damage (Shieh within the transcriptional activation region, which is required for the interaction of p53 with components of the et al., 1997; Siliciano et al., 1997). This site is a known will be important to continue to explore how N-terminal phosphorylation and kinases affect p53 stability and interaction with MDM2. Stress-induced changes are not relegated solely to the N terminus of p53, and several recent studies have reported alterations in C-terminal modification sites. Two groups reported that UV but not IR induces phosphorylation of murine Ser389 (Kapoor and Lozano, 1998; Lu et al., 1998) . Thus, as is the case with ATM, different types of DNA damage are relayed through discrete pathways to p53. Not only kinases are signaling targets: Waterman et al. (1998) made the interesting observation ing of p53 to 14-3-3 proteins and activation of sequenceand -20, and Thr18) and sites known to be phosphorylated in vitro specific DNA binding. Furthermore, DNA damage-inducby ATM, DNA-PK, or the cyclin-activating kinase complex, CAK, as ible acetylation of a C-terminal residue (Lys382) was indicated. C-terminal phosphorylation sites for CDK, PK-C and CKII recently reported (Sakaguchi et al., 1998) , showing that protein kinases, and PCAF and p300 acetyl transferases are indicated. Altered modification sites after DNA damage are shown in signaling is not exclusive to changes in phosphorylation.
yellow for phosphorylation sites and purple for acetylation site. Gray
How might these C-terminal modifications affect p53's regions indicate highly conserved regions on p53, including region function? As mentioned above, it has been known for I, which interacts with MDM2. some time that p53 can be isolated in a form that is virtually incapable of binding to DNA, due to the fact substrate for the DNA-activated protein kinase (DNAthat the highly basic p53 C terminus can negatively regu-PK). Although it is unclear whether DNA-PK phosphorylate the central sequence-specific DNA-binding region. lates p53 directly in vivo, the recent observation of Woo Phosphorylation of either cyclin-dependent kinase (CDK), et al. (1998) showing that p53 is inert as a transcriptional PK-C, or casein kinase II (CKII) sites within this region activator in cells lacking detectable DNA-PK activity relieves autorepression of the central domain by the C suggests that indeed DNA-PK is upstream of p53 and terminus. More recently it was also reported that aceis required for its transcription function. Ser15 has also tylation of p53 at C-terminal lysine residues accombeen shown to be phosphorylated by another kinase, plishes a similar result (Gu and Roeder, 1997 ; Sakaguchi the product of the ATM gene (Banin et al., 1998; Canman et al., 1998) . Both phosphorylation and acetylation are et al., 1998), that is defective in patients with ataxia likely to work by counteracting the effects of the highly telangiectasia (AT), a syndrome characterized by pleiopositively charged C terminus. However, noncovalent tropic phenotypes including extreme sensitivity to ionizmodifiers such as antibodies, short single strands of ing radiation. Importantly, ATM kinase activity is in-DNA, or the redox-repair protein, REF1, can also activate creased after DNA damage, providing a tantalizing hint latent p53. Since these experiments have for the most that ATM may phosphorylate p53 in vivo. Phosphorylapart been performed in vitro, it has been gratifying to tion of Ser15 is delayed in cells from AT patients (AT Ϫ identify altered modifications of p53 in vivo after stress cells) after gamma irradiation (IR) but not UV, suggesting signals that might lead to its activation. The fact that that ATM is important for signaling to p53, but in a the C terminus is subjected to multiple changes after DNA damage-specific manner (Siliciano et al., 1997) .
DNA damage lends credence to the concept that p53 Nevertheless, in AT Ϫ cells p53 does eventually become can exist in a latent state until it is needed to function phosphorylated at Ser15 after IR, indicating either that as a regulator of cell growth or death. Whether any given other kinases can substitute for ATM or that the kinetics modification results in selective activation of different of the bona fide primary Ser15 kinase (as yet unidentip53 functions or outcomes will be of considerable interfied) is regulated by ATM kinase. est in the future. Furthermore, it will be important to That Ser15 is a target for different protein kinases determine whether changes in p53 conformation due suggests that modification of this site is important for to C-terminal modification will be propagated to the altering p53 after DNA damage. Indeed, Shieh et al.
N-terminal region and thus affect its interaction with (1997) found that DNA damage-induced phosphoryla-MDM2. tion at Ser15, which lies at the N-terminal border of
The Discovery of ARF Explains How the MDM2 interaction region, weakens both the p53
Oncogenes Regulate p53 association with MDM2 and the ensuing ability of MDM2 How p53 becomes stabilized by viral and cellular oncoto repress transcriptional activation by p53. This obsergenes remained a complete mystery until quite recently. vation provides a paradigm for how DNA damage-
The discovery of the product of an ARF within the p16 prone, and their mouse embryo fibroblasts, like those Stanchina et al., 1998) . Indeed, the E1a result beautifully connects the Rb pathway to p53: by counteracting the lacking p53, are immortal (Kamijo et al., 1997) . Overexability of Rb to repress E2F, E1a promotes ARF activapression of p19 ARF in wild-type but not p53 Ϫ/Ϫ cells tion and consequent p53 stabilization. Consistent with causes cell cycle arrest, suggesting that ARF acts upthe observation that the p53 DNA damage-responsive stream of p53 (Kamijo et al., 1998) . Moreover, in wildpathway is intact in ARF Ϫ/Ϫ cells, de Stanchina et al. type cells ARF overexpression leads to increased levels (1998) have found that p53 phosphorylation on Ser15 of p53 and the p53 target gene, p21 (Kamijo et al., 1998) .
occurs in DNA-damaged, but not E1A-expressing, cells. Strikingly, however, in ARF Ϫ/Ϫ cells p53 induction and
Not only viral but also cellular oncogenes can regulate a p53 cellular response to DNA damage is intact (Kamijo p53 through ARF. have demonstrated et al., 1997). Thus, under some conditions ARF is rethat Myc, presumably working through an independent quired to induce p53, but its regulation of p53 is separate mechanism, can induce ARF. Intriguingly, Myc overexand independent from DNA damage-induced signaling pression in mouse embryo fibroblasts rapidly leads to to the p53 protein.
the appearance of variants that lose either ARF or p53 How does ARF induce p53? A number of studies have function giving rise to immortal cells that are resistant revealed direct physical interactions between ARF, p53, to Myc-induced apoptosis and that can be transformed and MDM2. Several groups (Kamijo et al. 1998; Pomer- by oncogenic Ras alleles alone . It is antz et al., 1998; Stott et al., 1998; Zhang et al., 1998) interesting to speculate that immortalization of primary have found that ARF binds to MDM2 and that trimeric fibroblasts by genes like E1a and Myc and their cotranscomplexes between p53, MDM2, and ARF can form in formation by Ras may depend in part on the ability of vivo. The N-terminal 62 amino acids of murine ARF are Myc and E1a to enforce selection of cells that have sufficient for it to bind to the C-terminus of MDM2 within dismantled the ARF-p53 checkpoint. This conjecture is a region not required for MDM2 association with p53 supported by the observation that overexpression of (Kamijo et al. 1998; Zhang et al., 1998) . However, conclup19 ARF counteracts the ability of Myc and Ras to transsions about the consequences of these interactions difform wild-type but not p53 Ϫ/Ϫ cells (Pomerantz et al. fer among the different investigators: Zhang et al. (1998) 1998). It is anticipated that yet additional pathways will reported that ARF can itself target MDM2 for degradaconnect oncogenes to p53 through ARF, and a recent tion. The other studies, however, do not suggest this as report from Palmero et al. (1998) suggests that Ras may a mechanism for how the association of ARF with MDM2 also be involved in this process. leads to increased quantities of p53, and more work will
The Complexity of p53 Circuitry be required to reveal the mode(s) of action of ARF on The studies described above are but another chapter MDM2 and p53.
in the continuing saga of deciphering p53. We now have With the excitement following the discovery that ARF further evidence that p53, a key cellular regulator, is regulates p53, researchers were keen to unearth how under the control of MDM2. But intricate circuitry is at ARF is itself triggered in cells. It is now clear that ARF is play here: p53 itself is instrumental in upregulating its induced by viral and cellular oncogenes, thereby counterinhibitor, MDM2, and also downregulating its activator, ing hyperproliferative signals by inducing p53-depen-ARF, as depicted in Figure 2 . It is well established that dent apoptosis. We can envisage a cellular pathway in MDM2 is itself a transcriptional target of p53 that is which ARF levels are regulated by the retinoblastoma induced after p53 becomes stabilized and activated. protein, Rb, another well-studied tumor suppressor (Fig- There is now evidence that p53 downregulates ARF unure 2). Normally, hypophosphorylated Rb binds and der normal conditions (Stott et al., 1998) . Thus, by interblocks the activity of members of the E2F family of acting with MDM2 and inhibiting ARF expression, p53 transcription factors, including E2F1. The E2Fs function levels are kept low during normal conditions. After to activate a number of genes required for passage into stress, modification of the p53 protein prevents or disand through S phase. Bates et al. (1998) now report that rupts the p53-MDM2 interaction, while as a result of E2F1 induces ARF expression most likely through its oncogene imbalance, ARF is induced and MDM2 is preability to activate the ARF promoter. The findings in vented from destabilizing p53. The outcome in both two current papers using mouse models, that E2F1 is cases, though, is increased and activated p53 protein. instrumental in regulating p53-mediated apoptosis (Pan Overlaid on the p53-MDM2 binary switch and its regulaet al., 1998; Tsai et al., 1998) , fit nicely with this obsertors is circuitry connecting the two tumor suppressors, vation.
p53 and Rb. Activation of p53 after DNA damage leads DNA tumor virus products can associate with Rb, disto G1 arrest that, through p21, occurs by maintenance rupting its ability to block passage of cells through G1 of active unphosphorylated Rb, which in turn restrains phase. It has now been shown that E1a induces ARF E2Fs. Thus, in this situation p53 can be seen as upexpression in cells, and importantly, the ability of E1a stream of Rb. E1a and T antigen can bind to and inactivate Rb, and both can stabilize p53 through the ARF to stabilize p53 is absent in ARF Ϫ/Ϫ fibroblasts (de 
